RECRUITING

Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI

Conditions

Contrast Induced Acute Kidney Injury Isuzinaxib APX-115 Contrast media ROS Acute Kidney Injury Percutaneous Coronary Intervention

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase 2 study is to assess the safety and efficacy of APX-115 active doses in Contrast Induced Acute Kidney Disease compared to placebo following multiple oral dosing in patients with undergoing percutaneous coronary intervention. It is anticipated that approximately 280 patients will be randomized into the study in a 1:1 ratio to 400 mg APX-115 (Isuzinaxib hydrochloride) or placebo arm.

Official Title

Effect on Contrast Induced Acute Kidney Injury of APX-115 in Subjects Undergoing Percutaneous Coronary Intervention A Randomized, Double-blind, Parallel Group, Multicenter, Multi-national Trial

Quick Facts

Study Start:2023-12-27

Study Completion:2024-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05758896

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Willing and able to provide informed consent. 2. Male or female, of any race or ethnicity, 18 years of age or older, inclusive, on the day of informed consent. Racial and ethnic minorities should be included in the study population to the greatest extent possible. 3. Diagnosed with coronary artery disease. 4. Planned to undergo coronary angiography within 4 weeks of being consented. 5. Risk of CKD evidenced by 30 mL/min/1.73m2 ≤ eGFR (Glomerular filtration rate) \< 90 mL/min/1.73 m2 confirmed by local or central laboratory. 6. Women of childbearing potential or males willing and able to use at least one protocol-specified method of contraception for the duration of their enrolment. 7. Subject is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the ICF.	1. Females who are pregnant or who are planning to become pregnant before the end of planned enrolment or who are breastfeeding. 2. Subjects who are not expected to go through PCI at the discretion of investigator or cardiologist 3. Subjects who have a history of hypersensitivity to contrast media or who cannot be administered contrast media according to investigator's discretion 4. Acute myocardial infarction within 1 month prior to Screening 5. ESRD confirmed by eGFR \< 15 mL/min/1.73 m2 at Screening. 6. Clinically significant heart disease as determined by the Investigator within 2 months prior to Screening including but not limited to any of following; cardiogenic shock, treatment requiring intra-aortic balloon pump (IABP) support, treatment with extra corporeal membrane oxygenation (ECMO), or NYHA class IV heart failure. 7. Uncontrolled treated/untreated hypertension (defined as systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg, mean of measured 2 times at Screening will be permitted). 8. Known or suspected hypersensitivity to any component of the APX-115 formulation. 9. History of acute kidney injury or renal dialysis within 1 month prior to Screening and/or plan to undergo a renal dialysis during enrolment. 10. Clinically apparent liver disease as determined by the Investigator (e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis) or moderate or severe hepatic impairment as determined by Child-Pugh score (Class B or C) at Screening. 11. Impaired liver function, defined as alanine aminotransferase (ALT) ≥ 2.5 times UNL or Total bilirubin \>1.5 × ULN, unless the subject has known Gilbert's syndrome. 12. Any sign or symptom of acute or chronic infection at Screening. 13. Receipt of any investigational drug within 4 weeks prior to Screening. 14. Confirmed or suspected abuse of alcohol or controlled substances within 1 year prior to Screening. 15. Clinically significant hematology abnormalities; hemoglobin \<9 g/dL for females or \<11 g/dL for males, absolute neutrophil count \<1500/mm3, platelet count \<100 × 109/L) at Screening. If any parameter is below the specified threshold, one hematology retest analyzed at the central or local laboratory within a week prior to randomization is permitted with the result of the last sample being conclusive. 16. Any other clinically significant medical condition or laboratory abnormality as determined by the Investigator that might jeopardize the safety of the subject, impair subject compliance, or impede safety/efficacy observations during enrolment. 17. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation with protocol requirements 18. Use of CYP1A2, CYP2B6 and CYP3A4 substrates or UGT inhibitors and inducers or OAT3 substrates prior to enrollment or concurrently. It will be only accepted to be eligible to screening if the subjects' concomitant medications will be reviewed and approved by the medical monitor and/or sponsor prior to the initial study dose

Inclusion Criteria

Exclusion Criteria

1. Willing and able to provide informed consent.
2. Male or female, of any race or ethnicity, 18 years of age or older, inclusive, on the day of informed consent. Racial and ethnic minorities should be included in the study population to the greatest extent possible.
3. Diagnosed with coronary artery disease.
4. Planned to undergo coronary angiography within 4 weeks of being consented.
5. Risk of CKD evidenced by 30 mL/min/1.73m2 ≤ eGFR (Glomerular filtration rate) \< 90 mL/min/1.73 m2 confirmed by local or central laboratory.
6. Women of childbearing potential or males willing and able to use at least one protocol-specified method of contraception for the duration of their enrolment.
7. Subject is aware of the investigational nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the ICF.

1. Females who are pregnant or who are planning to become pregnant before the end of planned enrolment or who are breastfeeding.
2. Subjects who are not expected to go through PCI at the discretion of investigator or cardiologist
3. Subjects who have a history of hypersensitivity to contrast media or who cannot be administered contrast media according to investigator's discretion
4. Acute myocardial infarction within 1 month prior to Screening
5. ESRD confirmed by eGFR \< 15 mL/min/1.73 m2 at Screening.
6. Clinically significant heart disease as determined by the Investigator within 2 months prior to Screening including but not limited to any of following; cardiogenic shock, treatment requiring intra-aortic balloon pump (IABP) support, treatment with extra corporeal membrane oxygenation (ECMO), or NYHA class IV heart failure.
7. Uncontrolled treated/untreated hypertension (defined as systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg, mean of measured 2 times at Screening will be permitted).
8. Known or suspected hypersensitivity to any component of the APX-115 formulation.
9. History of acute kidney injury or renal dialysis within 1 month prior to Screening and/or plan to undergo a renal dialysis during enrolment.
10. Clinically apparent liver disease as determined by the Investigator (e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis) or moderate or severe hepatic impairment as determined by Child-Pugh score (Class B or C) at Screening.
11. Impaired liver function, defined as alanine aminotransferase (ALT) ≥ 2.5 times UNL or Total bilirubin \>1.5 × ULN, unless the subject has known Gilbert's syndrome.
12. Any sign or symptom of acute or chronic infection at Screening.
13. Receipt of any investigational drug within 4 weeks prior to Screening.
14. Confirmed or suspected abuse of alcohol or controlled substances within 1 year prior to Screening.
15. Clinically significant hematology abnormalities; hemoglobin \<9 g/dL for females or \<11 g/dL for males, absolute neutrophil count \<1500/mm3, platelet count \<100 × 109/L) at Screening. If any parameter is below the specified threshold, one hematology retest analyzed at the central or local laboratory within a week prior to randomization is permitted with the result of the last sample being conclusive.
16. Any other clinically significant medical condition or laboratory abnormality as determined by the Investigator that might jeopardize the safety of the subject, impair subject compliance, or impede safety/efficacy observations during enrolment.
17. Mental incapacity, unwillingness, or language barrier precluding adequate understanding or cooperation with protocol requirements
18. Use of CYP1A2, CYP2B6 and CYP3A4 substrates or UGT inhibitors and inducers or OAT3 substrates prior to enrollment or concurrently. It will be only accepted to be eligible to screening if the subjects' concomitant medications will be reviewed and approved by the medical monitor and/or sponsor prior to the initial study dose

Contacts and Locations

Study Contact

Aptabio Therapeutics Inc.

CONTACT

+82313653693

cd@aptabio.com

Study Locations (Sites)

Florida Cardiovascular Research

Hialeah, Florida, 33012

United States

Sarkis Clinical Trials

Ocala, Florida, 34474

United States

Collaborators and Investigators

Sponsor: Aptabio Therapeutics, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-27

Study Completion Date2024-12-31

Study Record Updates

Study Start Date2023-12-27

Study Completion Date2024-12-31

Terms related to this study

Keywords Provided by Researchers

Isuzinaxib
APX-115
Contrast media
ROS
Acute Kidney Injury
Percutaneous Coronary Intervention

Additional Relevant MeSH Terms

Contrast Induced Acute Kidney Injury